Published in:
01-06-2015 | Original Article
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients
Authors:
Jeong Eun Kim, Yong Sang Hong, Jae-Lyun Lee, Kyu-Pyo Kim, Seong Joon Park, Sun Jin Sym, Dong Bok Shin, Jeeyun Lee, Young Suk Park, Jin Seok Ahn, Tae Won Kim
Published in:
Supportive Care in Cancer
|
Issue 6/2015
Login to get access
Abstract
Background
The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy. We compared the efficacy and safety of GTS with that of intravenous and oral granisetron in Korean patients receiving moderately emetogenic chemotherapy (MEC).
Patients and methods
A total of 276 patients were randomized into GTS (n = 139, one patch on days 1–4) or control group (n = 137, intravenous on day 1 and oral on days 2–4). The primary endpoint was the percentage of patients achieving complete response (CR) from chemotherapy initiation until 24 h after the final administration.
Results
Out of 234 patients (112 in GTS and 122 in control group) included in the per protocol analysis, 97.9 % had gastrointestinal cancer and 76.9 % received 3-day chemotherapy. The GTS showed non-inferior efficacy achieving CR in 75.0 % of the patients; 74.6 % of the patients in the control group achieved CR (95 % confidence interval −10.73 to 11.55 %). The CR rate did not change after subgroup analyses by sex, age, and chemotherapy naivety and analysis per day and overall days of treatment. The GTS group showed sustained CR from day 1 to day 4. Patients’ satisfaction, assessed using Functional Living Index—Emesis (FLI-E), showed no difference. Both treatments were well tolerated and safe.
Conclusion
The GTS showed non-inferior efficacy to intravenous and oral granisetron. The safety, tolerability, and FLI-E scores of the GTS were comparable to those of control group. The GTS offers a convenient alternative option for relieving CINV in patients receiving MEC.